U.S. Veterinary Oncology Market (2025 - 2030) Size, Share & Trends Analysis Report By Animal (Canine, Feline, Equine), By Therapy (Radiotherapy, Surgery, Chemotherapy, Immunotherapy), By Cancer Type, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                         1.1.1. Scope
                         1.1.2. Estimates And Forecast Timeline
                    1.2. Market Definitions
                    1.3. Research Methodology
                    1.4. Information Procurement
                         1.4.1. Purchased Database
                         1.4.2. GVR’s Internal Database
                    1.5. Market Formulation & Validation
                    1.6. Model Details
                         1.6.1. Commodity flow analysis
                         1.6.2. Global Market: CAGR Calculation
                    1.7. Research Scope and Assumptions
                         1.7.1. List of Secondary Sources
                         1.7.2. List of Primary Sources
                         1.7.3. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                         3.1.1. Parent Market Outlook
                         3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                         3.2.1. Market Drivers Analysis
                              3.2.1.1. Increasing Prevalence of Cancer in Pets
                              3.2.1.2. Increasing R&D In Pet Cancer Therapy
                              3.2.1.3. Growing Focus On Animal Safety
                              3.2.1.4. Growing Uptake Of Pet Insurance
                              3.2.1.5. Technological Advancements In Pet Cancer Treatment
                              3.2.1.6. Increase In Pet Population
                         3.2.2. Market Restraints Analysis
                              3.2.2.1. High cost of treatment
                              3.2.2.2. Adverse effects associated with therapies
                              3.2.2.3. Limited Clinical Evidence
                         3.2.3. Market Opportunity Analysis
                         3.2.4. Market Challenges Analysis
                    3.3. U.S. Veterinary Oncology Market Analysis Tools
                         3.3.1. Porter’s Analysis
                              3.3.1.1. Bargaining power of the suppliers
                              3.3.1.2. Bargaining power of the buyers
                              3.3.1.3. Threats of substitution
                              3.3.1.4. Threats from new entrants
                              3.3.1.5. Competitive rivalry
                         3.3.2. PESTEL Analysis
                              3.3.2.1. Political landscape
                              3.3.2.2. Economic and Social Landscape
                              3.3.2.3. Technological landscape
                              3.3.2.4. Environmental Landscape
                              3.3.2.5. Legal landscape
                    3.4. Covid-19 Analysis
                    3.5. Estimated pet population, by key species
Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Veterinary Oncology Market Movement Analysis
                    4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
                    4.4. Canine
                         4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    4.5. Feline
                         4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    4.6. Equine
                         4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Veterinary Oncology Market Movement Analysis
                    5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
                    5.4. Radiotherapy
                         5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                         5.4.2. Stereotactic Radiation Therapy
                              5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                              5.4.2.2. LINAC
                                   5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                              5.4.2.3. Other Type
                                   5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                         5.4.3. Conventional Radiation Therapy
                              5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    5.5. Surgery
                         5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    5.6. Chemotherapy
                         5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    5.7. Immunotherapy
                         5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    5.8. Other Therapies
                         5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Veterinary Oncology Market Movement Analysis
                    6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
                    6.4. Skin Cancer
                         6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    6.5. Lymphomas
                         6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    6.6. Sarcomas
                         6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
                    6.7. Others
                         6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Market Participant Categorization
                    7.2. Company Market Position Analysis/ Heat Map Analysis
                    7.3. Estimated Company Market Share Analysis, 2023
                    7.4. Strategy Mapping
                         7.4.1. Mergers & Acquisitions
                         7.4.2. Partnerships & Collaborations
                         7.4.3. Others
                    7.5. Company Profiles
                         7.5.1. Elanco
                              7.5.1.1. Participant’s Overview
                              7.5.1.2. Financial Performance
                              7.5.1.3. Product Benchmarking
                              7.5.1.4. Strategic Initiatives
                         7.5.2. Boehringer Ingelheim International GmbH.
                              7.5.2.1. Participant’s Overview
                              7.5.2.2. Financial Performance
                              7.5.2.3. Product Benchmarking
                              7.5.2.4. Strategic Initiatives
                         7.5.3. Zoetis
                              7.5.3.1. Participant’s Overview
                              7.5.3.2. Financial Performance
                              7.5.3.3. Product Benchmarking
                              7.5.3.4. Strategic Initiatives
                         7.5.4. PetCure Oncology
                              7.5.4.1. Participant’s Overview
                              7.5.4.2. Financial Performance
                              7.5.4.3. Product Benchmarking
                              7.5.4.4. Strategic Initiatives
                         7.5.5. Accuray Incorporated
                              7.5.5.1. Participant’s Overview
                              7.5.5.2. Financial Performance
                              7.5.5.3. Product Benchmarking
                              7.5.5.4. Strategic Initiatives
                         7.5.6. Varian Medical Systems, Inc.
                              7.5.6.1. Participant’s Overview
                              7.5.6.2. Financial Performance
                              7.5.6.3. Product Benchmarking
                              7.5.6.4. Strategic Initiatives
                         7.5.7. Elekta AB.
                              7.5.7.1. Participant’s Overview
                              7.5.7.2. Financial Performance
                              7.5.7.3. Product Benchmarking
                              7.5.7.4. Strategic Initiatives
                         7.5.8. Karyopharm Therapeutics, Inc.
                              7.5.8.1. Participant’s Overview
                              7.5.8.2. Financial Performance
                              7.5.8.3. Product Benchmarking
                              7.5.8.4. Strategic Initiatives
                         7.5.9. Virbac.
                              7.5.9.1. Participant’s Overview
                              7.5.9.2. Financial Performance
                              7.5.9.3. Product Benchmarking
                              7.5.9.4. Strategic Initiatives
                         7.5.10. Merck & Co., Inc.
                              7.5.10.1. Participant’s Overview
                              7.5.10.2. Financial Performance
                              7.5.10.3. Product Benchmarking
                              7.5.10.4. Strategic Initiatives
                         7.5.11. Dechra Pharmaceuticals PLC
                              7.5.11.1. Participant’s Overview
                              7.5.11.2. Financial Performance
                              7.5.11.3. Product Benchmarking
                              7.5.11.4. Strategic Initiatives
                         7.5.12. NovaVive Inc.
                              7.5.12.1. Participant’s Overview
                              7.5.12.2. Financial Performance
                              7.5.12.3. Product Benchmarking
                              7.5.12.4. Strategic Initiatives
                         7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
                              7.5.13.1. Participant’s Overview
                              7.5.13.2. Financial Performance
                              7.5.13.3. Product Benchmarking
                              7.5.13.4. Strategic Initiatives
Chapter 8. Key Takeaways

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
Table 4 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
Table 5 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
Table 6 Company Overview
Table 7 Service Benchmarking
Table 8 Financial Performance
Table 9 Strategic Initiatives

List of Figures

Fig. 1 U.S. Veterinary Oncology Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Data Analysis Models
Fig. 6 Market Formulation And Validation
Fig. 7 Data Validating & Publishing
Fig. 8 General methodology for a commodity flow analysis of the U.S. Veterinary Oncology Market
Fig. 9 Commodity flow analysis
Fig. 10 Parent market analysis
Fig. 11 Market Snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market value, 2024 (USD Billion)
Fig. 16 Ancillary market outlook, 2024
Fig. 17 U.S. Veterinary Oncology Market Dynamics
Fig. 18 Estimated animal population, 2018-2024 by key species and key countries
Fig. 19 U.S. Veterinary Oncology Market: PORTER’s analysis
Fig. 20 U.S. Veterinary Oncology Market: PESTEL analysis
Fig. 21 U.S. Veterinary Oncology Market by Animal: Key Takeaways
Fig. 22 U.S. Veterinary Oncology Market by Animal, 2024 & 2030
Fig. 23 Canine market, 2018 - 2030 (USD Million)
Fig. 24 Feline market, 2018 - 2030 (USD Million)
Fig. 25 Equine market, 2018 - 2030 (USD Million)
Fig. 26 Horses market, 2018 - 2030 (USD Million)
Fig. 27 U.S. Veterinary Oncology Market by Therapy: Key Takeaways
Fig. 28 U.S. Veterinary Oncology Market by Therapy, Market Share, 2024 & 2030
Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 31 LINAC market, 2018 - 2030 (USD Million)
Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
Fig. 34 Surgery market, 2018 - 2030 (USD Million)
Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
Fig. 38 U.S. Veterinary Oncology Market by Cancer Type: Key Takeaways
Fig. 39 U.S. Veterinary Oncology Market by Cancer Type, Market Share, 2024 & 2030
Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
Fig. 43 Other market, 2018 - 2030 (USD Million)
Fig. 44 Market Participant Categorization
Fig. 45 Heat map analysis
Fig. 46 Strategic Framework